SAB Biotherapeutics
SABS • NASDAQ
SAB Biotherapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Samuel J. Reich, with a market cap of $189.5M.
CEOSamuel J. Reich
Next Earnings
Upcoming earnings announcement for SAB Biotherapeutics
Date
Friday, March 27, 2026 (in 2 months)
Timing
After Market Close (6:00 PM New York)
Fiscal Period
Q4 2025
EPS Estimate
-$0.33
Revenue Estimate
$250.0K
Earnings History
Past 12 earnings reports for SAB Biotherapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2025 | Q3 2025 | -$0.21Est: -$0.51 | +58.8% | -Est: $250.0K | -100.0% |  10-Q |
| Aug 7, 2025 | Q2 2025 | -$1.09Est: -$0.82 | -32.9% | -Est: $260.0K | -100.0% | 10-Q |
| Mar 28, 2025 | Q4 2024 | -$1.23Est: -$1.21 | -1.7% | $114.7KEst: $120.0K | -4.4% | 10-K |
| Nov 6, 2024 | Q3 2024 | -$1.12Est: -$1.07 | -4.7% | -Est: $170.0K | -100.0% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.79Est: -$1.03 | +23.3% | $263.1K | — | 10-Q |
| May 20, 2024 | Q1 2024 | -$0.54Est: -$0.46 | -17.4% | $944.6K | — | 10-Q |
| Mar 29, 2024 | Q4 2023 | -$3.84Est: -$0.62 | -519.4% | $305.0K | — | 10-K |
| Nov 13, 2023 | Q3 2023 | -$1.00Est: -$1.20 | +16.7% | $1.3MEst: $20.0K | +6235.0% | — |
| Aug 21, 2023 | Q2 2023 | -$1.40 | — | $85.5K | — | 10-Q |
| May 16, 2023 | Q1 2023 | -$1.50Est: -$0.80 | -87.5% | $581.1KEst: $2.4M | -75.4% | 10-Q |
| Apr 14, 2023 | Q4 2022 | -$1.80Est: -$0.30 | -500.0% | $2.2MEst: $6.5M | -66.8% | — |
| Nov 15, 2022 | Q3 2022 | -$1.60Est: -$1.60 | 0.0% | $3.6MEst: $6.9M | -47.6% | — |